Epidermal Growth Factor Clinical Trials

16 recruitingLast updated: May 13, 2026

There are 16 actively recruiting epidermal growth factor clinical trials across 17 countries. Studies span Phase 2, Phase 1, Not Applicable. Top locations include Los Angeles, California, United States, Boston, Massachusetts, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Epidermal Growth Factor Trials at a Glance

16 actively recruiting trials for epidermal growth factor are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Los Angeles, Boston, and Nashville. Lead sponsors running epidermal growth factor studies include Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., Genmab, and EpiBiologics.

Browse epidermal growth factor trials by phase

Treatments under study

About Epidermal Growth Factor Clinical Trials

Looking for clinical trials for Epidermal Growth Factor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Epidermal Growth Factor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Epidermal Growth Factor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Non-small Cell Lung CancerStage IV Lung CancerStage III Lung Cancer+1 more
PrECOG, LLC.538 enrolled146 locationsNCT06538038
Recruiting
Phase 2

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Carcinoma, Non-Small Cell LungLeptomeningeal MetastasisEpidermal Growth Factor Receptor
Taipei Veterans General Hospital, Taiwan23 enrolled1 locationNCT05805631
Recruiting
Phase 2

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast CancerHER2-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
University of Chicago74 enrolled4 locationsNCT06348134
Recruiting
Phase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Breast CancerMetastatic Breast CancerBreast Neoplasms+6 more
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 2

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+2 more
Reshma L. Mahtani, D.O.75 enrolled3 locationsNCT06263543
Recruiting
Phase 2

Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

Non-small Cell Lung CancerEpidermal Growth Factor Receptor
Pusan National University Hospital70 enrolled1 locationNCT07073365
Recruiting
Phase 1Phase 2

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Glioblastoma MultiformeGlycolytic IndexEpidermal Growth Factor Receptor
Jonsson Comprehensive Cancer Center50 enrolled1 locationNCT06059690
Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Universitaire Ziekenhuizen KU Leuven39 enrolled1 locationNCT04216121
Recruiting

Observational Study of Afatinib 30 mg Daily

Non-small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore69 enrolled1 locationNCT04909073
Recruiting
Not Applicable

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University30 enrolled1 locationNCT06102928